In adult patients with HF LVEF ≥40% (HFmrEF & HFpEF)
Symptoms signal high risk of HF hospitalization or CV death—even in patients on current treatments4
Of patients presenting with symptomatic HF events in outpatient settings
Escalate to HF hospitalization or CV death5*
*Based on patients with HF LVEF >40% in a pivotal SGLT2i trial whose first presentation manifested as an outpatient oral diuretic intensification over a median of 2.3 years (n=789).5
CV=cardiovascular; HF=heart failure; HF LVEF=heart failure with left ventricular ejection fraction HFmrEF=heart failure with mildly reduced ejection fraction; HFpEF=heart failure with preserved ejection fraction; SGLT2i=sodium-glucose cotransporter 2 inhibitor.
HF hospitalization is a sentinel event1,5,6
There are >500,000 annual HF hospitalizations among US adults with HF LVEF ≥40%7
25%
Of patients were rehospitalized
due to HF within 1 year
of discharge9*
~2X
greater risk of CV mortality
with every additional
hospitalization3
Figure adapted from Greene et al. using findings and permission from Gheorghiade et al.2,8
Act now to reduce the risk of HF hospitalization, urgent HF visits, and CV death for your patients with HF LVEF ≥40%1
*Data based on the GWTG-HF registry linked to Centers for Medicare and Medicaid Services data from 2005 to 2011 with 1 year of follow-up.9
CV=cardiovascular; GWTG-HF=Get With The Guidelines®–Heart Failure; HF=heart failure; HF LVEF=heart failure with left ventricular ejection fraction.